HBA names Pfizer's Freda Lewis-Hall Woman of the Year

Share this article:
Pfizer's Freda Lewis-Hall, MD
Pfizer's Freda Lewis-Hall, MD
The Healthcare Businesswomen's Association named Pfizer chief medical officer Freda Lewis-Hall, MD its Woman of the Year for 2011.

Dr. Lewis-Hall, said HBA president Deborah Coogan Seltzer, “sets the tone for all of us with her unique abilities as a talented physician and leader. She has a longstanding commitment to the social responsibilities of healthcare leadership – especially in making sure that people have the education and understanding to make the best healthcare decisions.”

Lewis-Hall has personally mentored more than a hundred women over the course of her career, and has a strong record of patient advocacy, particularly around mental illness, said HBA. She has also been a vocal advocate for overcoming cultural barriers to care and eliminating healthcare disparities, having worked with members of the Health Brain Trust of the Congressional Black Caucus on those topics.

Last year, Lewis-Hall was named one of the inaugural members of the Board of Governors for the new Patient-Centered Outcomes Research Institute (PCORI), established under the Patient Protection and Affordable Care Act. She also serves on a number of boards, including the Society for the Advancement of Women's Health Research, the Foundation of the National Institutes of Health and the Board of Fellows of Harvard Medical School.

“Freda defines what it is to be a leader in today's rapidly changing healthcare industry,” said Pfizer president and CEO Ian Read, adding that she “is intensely engaged in critical policy dialog in the interest of better patient outcomes. We are fortunate to have her as our top physician ensuring the quality, safety and effective use of Pfizer medicines.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...